NEUROLIXIS

Neurolixis is an early-stage biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system disorders including Parkinson's disease, rare autism spectrum disorders, depression and pain... Neurolixis is privately held and funded by non-dilutive sources including research grants from foundations such as Parkinson's UK, the Michael J. Fox Foundation for Parkinson's Research, the US Department of Defense, the Rett Syndrome Research Trust and the International Rett Syndrome Foundation... Neurolixis Inc. is an early-stage biopharmaceutical company developing novel treatments for disorders of the central nervous system.

Also known as: Neurolixis, Inc.